JP2021522802A5 - - Google Patents

Info

Publication number
JP2021522802A5
JP2021522802A5 JP2020561923A JP2020561923A JP2021522802A5 JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5 JP 2020561923 A JP2020561923 A JP 2020561923A JP 2020561923 A JP2020561923 A JP 2020561923A JP 2021522802 A5 JP2021522802 A5 JP 2021522802A5
Authority
JP
Japan
Prior art keywords
composition according
treatment period
compound
hcv
days
Prior art date
Application number
JP2020561923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522802A (ja
JP7279081B2 (ja
JPWO2019217369A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031044 external-priority patent/WO2019217369A1/en
Publication of JP2021522802A publication Critical patent/JP2021522802A/ja
Publication of JP2021522802A5 publication Critical patent/JP2021522802A5/ja
Publication of JPWO2019217369A5 publication Critical patent/JPWO2019217369A5/ja
Application granted granted Critical
Publication of JP7279081B2 publication Critical patent/JP7279081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561923A 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法 Active JP7279081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668467P 2018-05-08 2018-05-08
US62/668,467 2018-05-08
PCT/US2019/031044 WO2019217369A1 (en) 2018-05-08 2019-05-07 Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect

Publications (4)

Publication Number Publication Date
JP2021522802A JP2021522802A (ja) 2021-09-02
JP2021522802A5 true JP2021522802A5 (https=) 2022-05-13
JPWO2019217369A5 JPWO2019217369A5 (https=) 2022-05-13
JP7279081B2 JP7279081B2 (ja) 2023-05-22

Family

ID=66625315

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561923A Active JP7279081B2 (ja) 2018-05-08 2019-05-07 Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法

Country Status (7)

Country Link
US (1) US12005120B2 (https=)
EP (1) EP3790972A1 (https=)
JP (1) JP7279081B2 (https=)
CN (1) CN112400020B (https=)
CA (1) CA3099698A1 (https=)
TW (1) TWI854980B (https=)
WO (1) WO2019217369A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113718024A (zh) * 2020-05-26 2021-11-30 深圳市血液中心 血浆miRNA标志物及其应用
KR20240166519A (ko) * 2022-03-25 2024-11-26 한서 바이오 엘엘씨 치료제의 표적화된 전달을 위한 비사이클릭 헤테로사이클 및 이의 리간드

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503364A (ja) 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
AU1039397A (en) 1995-11-22 1997-06-27 Johns Hopkins University, The Ligands to enhance cellular uptake of biomolecules
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
IL148916A0 (en) 1999-10-04 2002-09-12 Exiqon As Design of high affinity rnase h recruiting oligonucleotide
US20020068709A1 (en) 1999-12-23 2002-06-06 Henrik Orum Therapeutic uses of LNA-modified oligonucleotides
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
CN1344803A (zh) 2001-09-27 2002-04-17 吴昌 核酸靶分子选择及扩增方法
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
RU2377301C2 (ru) 2003-12-23 2009-12-27 Сантарис Фарма А/С ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА
AU2005325262B2 (en) 2004-04-27 2011-08-11 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
ES2361458T5 (es) 2004-05-04 2016-04-20 The Board Of Trustees Of The Leland Stanford Junior University Procedimientos y composiciones para reducir las cantidades de genoma vírico de VHC en una célula diana
CA2574603C (en) 2004-08-04 2014-11-04 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20090203132A1 (en) 2004-09-09 2009-08-13 Swayze Eric E Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
EP1841867A1 (en) 2005-01-24 2007-10-10 Avaris AB COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007021896A2 (en) 2005-08-10 2007-02-22 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
CA2620856C (en) 2005-08-29 2017-11-28 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP2666859B1 (en) 2006-04-03 2019-01-02 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2648132C (en) 2006-04-03 2019-05-28 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2152879B1 (en) 2007-05-01 2012-11-14 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
JP5872162B2 (ja) 2007-11-26 2016-03-01 エンゾン ファーマシューティカルズ，インコーポレーテッド アンドロゲン受容体を標的化するｌｎａアンタゴニスト
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
JP5793423B2 (ja) 2008-12-31 2015-10-14 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ 急性冠症候群の治療のためのＬＮＡＡｐｏＢアンチセンスオリゴマーの使用
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
CA2765129A1 (en) 2009-06-08 2010-12-16 Miragen Therapeutics Chemical modification motifs for mirna inhibitors and mimetics
KR20120095397A (ko) 2009-10-16 2012-08-28 글락소 그룹 리미티드 Ｈｂｖ 안티센스 억제제
DK2539451T3 (da) 2010-02-24 2016-04-04 Arrowhead Res Corp Sammensætninger til målrettet tilførsel af siRNA
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011130458A2 (en) 2010-04-13 2011-10-20 John Rossi Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
CA2812046A1 (en) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Modified irna agents
EP2652134B1 (en) 2010-12-17 2017-03-01 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
ES2605990T3 (es) 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
EP3211082B1 (en) 2011-04-25 2021-02-17 Sanofi Microrna compounds and methods for modulating mir-21 activity
US20140248611A1 (en) 2011-06-16 2014-09-04 Nippon Steel & Sumikin Eco-Tech Corporation Nucleic acid probe for assaying nucleic acids
US20140127159A1 (en) * 2011-06-23 2014-05-08 Stella Aps HCV Combination Therapy
KR20140064765A (ko) 2011-06-30 2014-05-28 스텔라 에이피에스 Hcv 조합 치료
EP2726611A1 (en) 2011-06-30 2014-05-07 Stella ApS Hcv combination therapy
EP3453761A1 (en) * 2011-08-29 2019-03-13 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
EP2776590B1 (en) 2011-11-07 2016-10-26 Roche Innovation Center Copenhagen A/S Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN104955950B (zh) 2012-09-26 2019-04-26 米尔克斯治疗学公司 具有改善的脱靶特征谱的寡核苷酸
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CN104955952A (zh) 2013-01-30 2015-09-30 弗·哈夫曼-拉罗切有限公司 Lna寡核苷酸碳水化合物缀合物
CN105164261B (zh) 2013-05-01 2022-03-18 莱古路斯治疗法股份有限公司 用于增强的细胞摄取的化合物和方法
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression

Similar Documents

Publication Publication Date Title
Gentile et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir
JP2008518943A5 (https=)
JP2010503396A5 (https=)
JP2021521118A5 (https=)
AR079555A1 (es) Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv)
Bourlière et al. Sofosbuvir as backbone of interferon free treatments
CN108712905B (zh) 抗肝肿瘤病毒剂
WO2010031832A9 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
TW200815384A (en) Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
KR20120139699A (ko) Ｃ형 간염 바이러스 감염의 치료 요법
JP2013540112A (ja) Ｈｃｖ感染を治療するための併用療法
JP2011522862A (ja) テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
JP2021522802A5 (https=)
Schinazi et al. Sofosbuvir (sovaldi): The first‐in‐class HCV ns5b nucleotide polymerase inhibitor
US10471048B2 (en) Thienopyridine derivative for the treatment of hepatitis C infections
JPWO2019217369A5 (https=)
US20130028865A1 (en) Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
WO2014033668A2 (en) Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
JP2021523129A5 (https=)
Garg et al. Management of HCV infection: current issues and future options
Reviriego Daclatasvir dihydrochloride
US10201541B1 (en) Compositions and methods for treating HCV
US20130273003A1 (en) Therapies for Treating Hepatitis C Virus Infection
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
Kaur et al. Emerging therapies in pipeline for chronic hepatitis C